CSTL - NASDAQ
Castle Biosciences, Inc.
$20.39
+3.4%Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.
At a Glance
Live SnapshotCastle Biosciences, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Negative free cash flow despite positive earnings raises concerns about cash generation ability or heavy capital requirements.
CapEx Intensity
Capital-intensive operations require significant reinvestment. Monitor whether CapEx is maintenance or growth-oriented.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Cash Flow Quality Insight
Deteriorating cash generation: Both declining FCF and weak conversion rate signal fundamental challenges. Investigate margin pressure, rising costs, or working capital issues.
Castle Biosciences, Inc. Cash Flow Statement
CSTL • NASDAQ
| Castle Biosciences, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 |
|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | |||||||||
-24.2M | 18.2M | -57.5M | -67.1M | -31.3M | -10.3M | 5.3M | -6.4M | -12.4M | |
40.8M | 16M | 12.3M | 10.5M | 3.4M | 472K | 358K | 323K | 310.8K | |
-6.2M | 1.4M | -223K | -1.9M | -8.7M | 0.0 | -2.3M | 272.4K | -163.3K | |
45.9M | 50.3M | 51.2M | 36.3M | 21.7M | 8.3M | 1.2M | 293.6K | 108.7K | |
-5.5M | -7M | -4.9M | -19.5M | 0.0 | 2.2M | 2.4M | 542.4K | 520.2K | |
(0.0) | (2.5M) | (198K) | (120K) | (16K) | (102K) | (150K) | (160K) | (0.0) | |
13.6M | -14.1M | -6.6M | -7K | -4.1M | 9.1M | 44K | -7.4M | -640.5K | |
64.3M | 64.9M | -5.6M | -41.7M | -19M | 9.9M | 7M | -12.3M | -12.2M | |
INVESTING ACTIVITIES | |||||||||
-36M | -28.3M | -13.6M | -5.6M | -3.5M | -4.8M | -937K | -277K | -494.9K | |
-18.7M | (18K) | (0.0) | -27M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-188.7M | -205.7M | -189.1M | -134.7M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
190.7M | 183.9M | 186.5M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
-7.6M | 0.0 | 13K | 742K | -63.2M | 3K | 0.0 | 0.0 | 0.0 | |
-60.4M | -50.1M | -16.2M | -166.5M | -66.7M | -4.7M | -937K | -277K | -494.9K | |
FINANCING ACTIVITIES | |||||||||
2.2M | 2M | 0.0 | 0.0 | 0.0 | 330M | 65.9M | 37.2K | 0.0 | |
-115K | 9.9M | -142K | -122K | -8K | -27.4M | 20.9M | 5.4M | 8.6M | |
-9.1M | -5.8M | -2.2M | 1.6M | 5.4M | 3.2M | 1.4M | 0.0 | 3.6K | |
-7M | 6.1M | -2.3M | 1.5M | 5.4M | 305.9M | 88.3M | 15.8M | 8.9M | |
CASH FLOW SUMMARY | |||||||||
-3M | 20.9M | -24.1M | -206.7M | -80.2M | 311M | 94.4M | 3.3M | -3.9M | |
119.7M | 98.8M | 122.9M | 329.6M | 409.9M | 98.8M | 4.5M | 1.2M | 5.1M | |
116.7M | 119.7M | 98.8M | 122.9M | 329.6M | 409.9M | 98.8M | 4.5M | 1.2M | |
28.3M | 36.5M | -19.2M | -47.3M | -22.5M | 5.1M | 6.1M | -12.6M | -12.7M |
SEC Filings
CSTL - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 29, 2026 | May 28, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 06, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 06, 2026 | May 06, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 08, 2026 | May 28, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 26, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 26, 2026 | February 26, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 13, 2026 | January 11, 2026 | 2026 | |
10-Q 10-Q 2025 Q3 Q3 | November 03, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 03, 2025 | November 03, 2025 | 2025 | |
8-K 8-K 2025 N/A | August 08, 2025 | August 05, 2025 | 2025 |
Related Guides
Continue your CSTL research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.